The LJWG 2014 conference is funded through educational grants from AbbVie Ltd, Gilead Sciences Ltd and MSD Ltd
and sponsored by Bristol-Myers Squibb. None of the sponsors has had any control over the agenda or content.
Hepatitis C in London:
practical steps to elimination
Monday 17th November 2014
Guildhall, London
Hepatitis C in London:
practical steps to elimination
Co-Chairs:
Cllr Victoria Borwick
Deputy Mayor of London
Dr Ashley Brown
Consultant Hepatologist, St. Mary’s and Hammersmith Hospitals London
and Honorary Senior Lecturer, Imperial College London
#LJWG2014
SESSION 1
Tools to eliminate
Tackling Hepatitis
what PHE modelling shows us
Dr Helen Harris
Clinical Scientist & Research Associate,
Public Health England
Data collection
and barriers in the system
Dee Cunniffe
Policy Lead & Co-facilitator
London Joint Working Group on Substance Use and Hepatitis C
How aspirations can be built and
levels of performance can be
assured:
learning from the Scottish Action Plan
Professor Sharon Hutchinson
Professor of Epidemiology & Population Health
Glasgow Caledonian University
Health Protection Scotland
Needle exchange
impact on hepatitis C pathways
Mike Burns
CEO & Operations Director
CAIR Scotland
Supporting people who
use drugs and providers:
Hep C info and care
Dr Magdalena Harris
Qualitative Sociologist
London School of Hygiene & Tropical Medicine
The role of technology
in supporting patient pathways
Claire Munro
Co-facilitator
London Joint Working Group on Substance Use and Hepatitis C
RCGP training online:
new training in short bites
Danny Morris
RCGP Clinical Lead
Hepatitis B & C, Part 1 certificate
Hepatitis C in London:
practical steps to elimination
QUESTIONS
Dr Ashley Brown
Consultant Hepatologist, St. Mary’s and Hammersmith Hospitals, London
and Honorary Senior Lecturer, Imperial College London
Hepatitis C in London:
practical steps to elimination
REFRESHMENT BREAK
SESSION 2
Collaborate to eliminate
Producing a framework
for hepatitis C
through partnership working
Dr Éamonn O’Moore
Head of Health & Justice
Health & Wellbeing Directorate
Public Health England
The role of drug treatment
providers in the care pathway:
practical learning from the South-West
David Badcock
Head of Recovery Engagement
Addaction
Reducing transmission
in PWID
by scaling up drug treatment, OST
and needle exchange services
Professor Matt Hickman
Professor of Public Health & Epidemiology
University of Bristol
The Updated LJWG
Consensus
Dr Ashley Brown
Consultant Hepatologist, St. Mary’s and Hammersmith Hospitals, London
and Honorary Senior Lecturer, Imperial College London
Hepatitis C in London:
practical steps to elimination
QUESTIONS
Cllr Victoria Borwick
Deputy Mayor of London
WORKSHOPS
Hepatitis C policy development
- East Crypt (adjacent to Livery Hall)
How to reduce blockages in the system by implementing care
pathways in collaboration with commissioners
- West Crypt (walk through the East Crypt)
The impact of new drug treatments on elimination
- Livery Hall (main plenary)
Community mobilisation: engaging users to support needle
exchanges and peer-led groups
- City Marketing Suite Conference Room (outside and right)
Hepatitis C in London:
practical steps to elimination
LUNCH
The LJWG 2014 conference is funded through educational grants from AbbVie Ltd, Gilead Sciences Ltd and MSD Ltd
and sponsored by Bristol-Myers Squibb. None of the sponsors has had any control over the agenda or content.
Hepatitis C in London:
practical steps to elimination
WORKSHOP FEEDBACK
Chair:
Charles Gore
President, World Hepatitis Alliance
Chief Executive, Hepatitis C Trust
The impact of new
drugs on elimination
Dr Suman Verma
Institute of Liver Studies
King's College Hospital London
New Drugs for HCV - key messages
• A tornado of new drugs
• Combinations of drugs
together work best
• Less role of interferon
• 8-12 weeks duration
• Real life is not as per the trials
• Access & affordability
• The future is bright but the
timelines unclear…
Hepatitis C
policy development
Chris Kelly
Assistant Head of Health & Justice Commissioning
NHS England
Hepatitis C policy development
Solutions to policy challenges
Chris Kelly, NHS England
1. Low public and GP awareness – education programmes, campaigns, training
2. Policy deprioritisation – overarching policy initiatives eg Health Check,
Outcomes Framework
3. Inflexible services/time pressures – care navigators, community prescribing,
digital access to information
4. Opaque commissioning – clearer guidance, ensuring strategies in place for
longer than duration of tenders, focusing on service delivery and integration
How to reduce
blockages in the system
by implementing care pathways in
collaboration with commissioners
Emma Burke
Alcohol & Drugs Programme Manager
Public Health England
Reducing blockages in the pathway
Blockages:
• Lack of understanding
commissioning & where the
funding comes from
• No recourse to public funds
• Treatment too difficult to access
• Tension between local and
national priorities
• Short-term planning and
commissioning
• Skills and education all along
the pathway (staff and service
users, commissioners)
Solutions:
• Clarify role of CCGs, NHSE &
Local Authorities, and funding
for new treatments
• London-wide Commissioning
and pathways
• Deliver treatment ‘near the
service user’ / in the community
/ possibly by pharmacist
• Need a national driver and
long-term plans
• Education and formal training
• Build Peer-support and user
voice
Community
mobilisation:
engaging users to support needle
exchanges and peer-led groups
Mat Southwell
Partner
Coact
Community Mobilisation
Engaging people who use drugs to support
needle exchanges & peer led groups
•Mat Southwell
•Partner Coact
www.co-act.info
Community mobilisation NSPs
• Peer led NSPs
• Meaningful participation in traditional
NSPs
• Secondary needle exchange
• Supplier engagement
matsouthwell@co-act.info
Final panel
• Mike Burns
CEO & Operations Director, CAIR Scotland
• Jim Conneely
Hepatitis C Patient and Hepatitis C Trust outreach worker
• Professor Graham Foster
Professor of Hepatology and Consultant Hepatologist, Bart’s and The Royal London
Hospitals, London
• Professor Matt Hickman
Professor of Public Health and Epidemiology, University of Bristol
• Peter Kohn
Director, London Office of Clinical Commissioning Groups
• Dr Éamonn O’Moore
Head of Health & Justice, Health & Wellbeing Directorate, Public Health England
• Dr Sally Porter
Consultant in Addiction Psychiatry, South London and Maudsley NHS Foundation Trust, and
Turning Point
The LJWG 2014 conference is funded through educational grants from AbbVie Ltd, Gilead Sciences Ltd and MSD Ltd
and sponsored by Bristol-Myers Squibb. None of the sponsors has had any control over the agenda or content.